- The Indian government has proposed amendments to mandate the immediate suspension of manufacturing licences for substandard or adulterated drugs to protect public health. - Current regulatory provisions often involve protracted legal and procedural delays before errant manufacturing units face suspension or cancellation. - The move aims to strengthen India's pharmaceutical quality control framework, ensuring higher compliance with Good Manufacturing Practices (GMP). - This reform is critical for maintaining international confidence in India's reputation as the pharmacy of the world. - **Drugs and Cosmetics Act:** Principal central legislation governing the import, manufacture, distribution, and sale of drugs and cosmetics in India, designed to prevent substandard and spurious products and ensure public safety. - **Central Drugs Standard Control Organisation:** National regulatory body under the Ministry of Health and Family Welfare responsible for ensuring the safety, quality, and efficacy of drugs, medical devices, and cosmetics nationwide. - **Ministry of Health and Family Welfare:** The central government department in charge of formulating national health policy, overseeing public health programs, and regulating medical infrastructure and pharmaceutical standards across India. **Introduction** The Indian government has proposed strict regulatory amendments to enable the immediate suspension of manufacturing licences for substandard and spurious drugs. Addressing existing procedural bottlenecks, the move aims to enhance pharmaceutical quality assurance, enforce Good Manufacturing Practices (GMP), and safeguard patient safety against the circulation of sub-standard medications. **Core Issue and Detailed Points** - The Indian government has proposed amendments to mandate the immediate suspension of manufacturing licences for substandard or adulterated drugs to protect public health. - Current regulatory provisions often involve protracted legal and procedural delays before errant manufacturing units face suspension or cancellation. - The move aims to strengthen India's pharmaceutical quality control framework, ensuring higher compliance with Good Manufacturing Practices (GMP). - This reform is critical for maintaining international confidence in India's reputation as the pharmacy of the world. **Key Statutory Bodies, Acts & Concepts** - **Drugs and Cosmetics Act:** Principal central legislation governing the import, manufacture, distribution, and sale of drugs and cosmetics in India, designed to prevent substandard and spurious products and ensure public safety. - **Central Drugs Standard Control Organisation:** National regulatory body under the Ministry of Health and Family Welfare responsible for ensuring the safety, quality, and efficacy of drugs, medical devices, and cosmetics nationwide. - **Ministry of Health and Family Welfare:** The central government department in charge of formulating national health policy, overseeing public health programs, and regulating medical infrastructure and pharmaceutical standards across India.